Human Immunodeficiency Virus Type 1 Market 2024-2034
                     Human 
Immunodeficiency 
Virus Type 1 Market 
Research Report 
2024-2034
ABOUT IMARC
International Market Analysis Research and 
Consulting Group is a leading adviser on 
management strategy and market research 
worldwide. We partner with clients in all regions and 
industry verticals to identify their highest-value 
opportunities, address their most critical challenges, 
and transform their businesses.
IMARC’s information products include major market, 
scientific, economic and technological developments 
for business leaders in pharmaceutical, industrial, 
and high technology organizations. Market forecasts 
and industry analysis for biotechnology, advanced 
materials, chemicals, food and beverage, travel and 
tourism, nanotechnology and novel processing 
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable 
insight into the dynamics of companies and markets 
with close cooperation at all levels of the client 
organization. This ensures that our clients achieve2 
unmatchable competitive advantage, build more 
proficient organizations, and secure lasting results.
Report Description and Highlights
Human Immunodeficiency Virus Type 1 Market Report Overview:
• Report Attribute                       Details
• Base Year                                         2023
• Forecast Years                        2024-2034
• Historical Years                        2018-2023
• Market Size in 2023                       US$ 24.4 Billion
• Market Forecast in 2034               US$ 39.8 Billion
• Market Growth (2024-2034)       4.56%
The report offers a comprehensive analysis of the Human Immunodeficiency Virus Type 1 market in the United States, EU5 (including 
Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the 
market, drugs in development, the proportion of various therapies, and the market's performance in the seven major regions. Additionally, 
the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across 
these key markets are also detailed in the report. 3
Report Description and Highlights
This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone 
interested or involved in the Human Immunodeficiency Virus Type 1 market.
Market Overview:
The 7 major human immunodeficiency virus type 1 markets reached a value of US$ 24.4 Billion in 2023. Looking 
forward, IMARC Group expects the 7MM to reach US$ 39.8 Billion by 2034, exhibiting a growth rate (CAGR) of 
4.56% during 2024-2034.
4
Report Description and Highlights
Human immunodeficiency virus type 1 (HIV-1) is a retrovirus that primarily targets immune system cells, 
notably CD4+ T-helper cells crucial for orchestrating the body’s response to infections. The market for human 
immunodeficiency virus type 1 is experiencing robust growth, driven by various key factors. Firstly, 
advancements in medical research and technology have resulted in the development of more effective 
antiretroviral therapies (ART) for treating HIV-1. These therapies not only enhance the quality of life for HIV-1 
patients but also contribute to the overall expansion of the market. Increased awareness and education about 
human immunodeficiency virus type 1 prevention and early detection are vital drivers for market growth. 
Public health campaigns and initiatives have significantly reduced the stigma associated with HIV-1, 
encouraging more individuals to undergo testing and seek treatment. Consequently, this has led to a larger 
patient pool and an escalated demand for human immunodeficiency virus type 1 medications and therapies. 
Government initiatives and funding for human immunodeficiency virus type 1 research and treatment 
programs have also significantly boosted market growth.
Countries worldwide are committed to ending the HIV-1 epidemic by 2030, investing in healthcare5 
infrastructure to improve access to treatments and prevention methods. 
Report Description and Highlights
The rise in population and increasing high-risk behaviors, such as unprotected sexual intercourse, also 
contribute to the growth of the human immunodeficiency virus type 1 market. These factors heighten the risk 
of HIV-1 transmission, driving demand for preventative measures and medications. Additionally, the 
pharmaceutical industry’s commitment to human immunodeficiency virus type 1 R&D has introduced novel 
drugs and therapies, stimulating market expansion. The emergence of long-acting injectable medication and 
ongoing HIV-1 cure research further fuel market optimism. These drivers are anticipated to continue fostering 
growth in the human immunodeficiency virus type 1 market, offering hope for improved treatment options 
and, ultimately, a cure for this devastating virus.
Request a Sample Report: 
https://www.imarcgroup.com/human-immunodeficiency-virus-type-1-market/requestsample
6
Report Description and Highlights
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2032
Countries Included:
• United States
• Germany
• France
7
Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Human Immunodeficiency Virus Type 1 market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Human Immunodeficiency Virus Type 1 market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current Human Immunodeficiency Virus Type 1 
marketed drugs and late-stage pipeline drugs.
8
Report Description and Highlights
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
View Report TOC, Figures and Tables: 
https://www.imarcgroup.com/human-immunodeficiency-virus-type-1-market 9
Report Description and Highlights
Competitive Landscape With Key Players:
The competitive landscape of the Human Immunodeficiency Virus Type 1 market has been studied in the report 
with the detailed profiles of the key players operating in the market.
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: 
https://www.imarcgroup.com/request?type=report&id=8722&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as 
a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research 
worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, 
address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for 
business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and 
industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and 
tourism, nanotechnology and novel processing methods are at the top of the company’s expertise. 1
0
Report Description and Highlights
Media Contact:
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: [email protected]
Phone: +1-631-791-1145
Address: 134 N 4th St
City: Brooklyn
State: NY
Country: United States
Website: https://www.imarcgroup.com/
1
1
Key Questions Answered in the Report
1. How has the Human Immunodeficiency Virus Type 1 market performed so far and how will it perform in the 
coming years?
2. What are the markets shares of various therapeutic segments in 2023 and how are they expected to 
perform till 2034?
3. What was the country-wise size of the Human Immunodeficiency Virus Type 1 market across the seven 
major markets in 2023 and what will it look like in 2034?
4. What is the growth rate of the Human Immunodeficiency Virus Type 1 market across the seven major 
markets and what will be the expected growth over the next ten years?
5. What are the key unmet needs in the market?
12
Table of 
Contents
Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
14
Table of Contents
4 Human Immunodeficiency Virus Type 1 - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Human Immunodeficiency Virus Type 1 - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
    
Click here to visit the complete table of content with list of figures and tables: 
https://www.imarcgroup.com/human-immunodeficiency-virus-type-1-market/toc
15
Partial List Of Our Clients
16
OUR CLIENTS
17
Disclaimer
© 2024 IMARC All Rights Reserved 
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of 
International Market Analysis Research and Consulting (IMARC). No part of this publication may be 
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be 
used in any form or by and means graphic electronic or mechanical, including photocopying, recording, 
taping or by information storage or retrieval, or by any other form, without the express consent of 
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion 
have been based on information and sources believed to be accurate and reliable at the time of 
publishing. International Market Analysis Research and Consulting makes no representation of warranty 
of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability 
whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this 
publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International 
Market Analysis Research and Consulting. All other trademarks used in this publication are registered 
1
trademarks of their respective companies. 8